摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

ethyl 1-benzyl-1-azoniabicyclo[3.3.1]-non-5-ylcarboxylate bromide | 119137-79-0

中文名称
——
中文别名
——
英文名称
ethyl 1-benzyl-1-azoniabicyclo[3.3.1]-non-5-ylcarboxylate bromide
英文别名
1-benzyl-5-(ethoxycarbonyl)-1-azoniabicyclo[3.3.1]nonane bromide;ethyl 1-benzyl-1-azoniabicyclo[3.3.1]nonane-5-carboxylate;bromide
ethyl 1-benzyl-1-azoniabicyclo[3.3.1]-non-5-ylcarboxylate bromide化学式
CAS
119137-79-0
化学式
Br*C18H26NO2
mdl
——
分子量
368.314
InChiKey
NSUGIIDLBFVZIY-UHFFFAOYSA-M
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.14
  • 重原子数:
    22
  • 可旋转键数:
    5
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.61
  • 拓扑面积:
    26.3
  • 氢给体数:
    0
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Novel compounds
    摘要:
    化学式(I)的化合物或其药学上可接受的盐:##STR1## 其中X代表R.sub.1 OOC--,其中R.sub.1是C.sub.1-4烷基,C.sub.2-4烯基或C.sub.2-4炔基;R.sub.2 O--其中R.sub.2是C.sub.1-2烷基,C.sub.1-2烷基羰基或氨基羰基,可选择地被一个或两个甲基基团取代;一个基团##STR2## 其中Y代表一个3-成员二价残基,完成一个5-成员芳香环并包括一个或两个从氧、氮和硫中选择的杂原子,任何氨基氮可选择地被一个C.sub.1-2烷基基团取代,Y可选择地被一个甲基基团取代;或一个基团##STR3## 其中A.sub.1是氧或硫,A.sub.2和A.sub.3中的一个是CR.sub.3,另一个是氮或CR.sub.4,其中R.sub.3和R.sub.4分别独立地选择自氢和甲基;每个p和q独立地表示2到4的整数。
    公开号:
    US04971975A1
  • 作为产物:
    参考文献:
    名称:
    EP2119716
    摘要:
    公开号:
点击查看最新优质反应信息

文献信息

  • Heterocyclic azabicyclic compounds for enhancing acetylcholine function
    申请人:Beecham Group p.l.c.
    公开号:US05132316A1
    公开(公告)日:1992-07-21
    A compound of formula (I) or a pharmaceutically acceptable salt thereof: ##STR1## in which X represents R.sub.1 OOC-- in which R.sub.1 is C.sub.1-4 alkyl, C.sub.2-4 alkenyl or C.sub.2-4 alkynyl; R.sub.2 O-- in which R.sub.2 is C.sub.1-2 alkyl, C.sub.1 -2 alkylcarbonyl or aminocarbonyl optionally substituted by one or two methyl groups; a group ##STR2## in which Y represents a 3-membered divalent residue completing a 5-membered aromatic ring and comprises one or two heteroatoms selected from oxygen, nitrogen and sulphur, any amino nitrogen optionally substituted by a C.sub.1-2 alkyl group, Y being optionally C-substituted by a methyl group; or a group ##STR3## in which A.sub.1 is oxygen or sulphur, one of A.sub.2 and A.sub.3 is CR.sub.3 and the other is nitrogen or CR.sub.4 where R.sub.3 and R.sub.4 are independently selected from hydrogen and methyl; and each of p and q independently represents an integer of 2 to 4.
    化合物的化学式(I)或其药学上可接受的盐:##STR1## 其中X代表R.sub.1 OOC--,其中R.sub.1是C.sub.1-4烷基,C.sub.2-4烯基或C.sub.2-4炔基; R.sub.2 O--,其中R.sub.2是C.sub.1-2烷基,C.sub.1-2烷基羰基或氨基羰基,可选择地被一个或两个甲基基团取代的氨基; 一个基团##STR2## 其中Y代表一个3元二价残基,完成一个5元芳香环,并包含来自氧,氮和硫的一个或两个杂原子,任何氨基氮可选择地被C.sub.1-2烷基基团取代,Y可选择地被甲基基团取代; 或一个基团##STR3## 其中A.sub.1是氧或硫,A.sub.2和A.sub.3中的一个是CR.sub.3,另一个是氮或CR.sub.4,其中R.sub.3和R.sub.4独立地选择自氢和甲基; p和q各自独立地表示2到4的整数。
  • AZA-BRIDGED-RING COMPOUND
    申请人:Nagashima Shinya
    公开号:US20100105658A1
    公开(公告)日:2010-04-29
    [Problems] Provided is a compound which has an antagonistic action on a muscarinic M 3 receptor and is useful as an active ingredient of a prophylactic and/or therapeutic agent for an inflammatory disease such as a chronic obstructive pulmonary disease (COPD), asthma and the like. [Means for Solving Problems] The present inventors have made studies on a compound having an antagonistic action on the binding of a muscarinic M 3 receptor, and they have found that an aza-bridged-ring compound or a salt thereof has an antagonistic action on the binding of a muscarinic M 3 receptor, thereby completing the present invention. The aza-bridged-ring compound of the present invention has an antagonistic action on the binding of a muscarinic M 3 receptor, and can be used as a prophylactic and/or therapeutic agent for an inflammatory disease such as a chronic obstructive pulmonary disease (COPD), asthma and the like.
    【问题】提供了一种具有抗胆碱能M3受体拮抗作用的化合物,可作为预防和/或治疗慢性阻塞性肺疾病(COPD)、哮喘等炎症性疾病的活性成分。 【解决问题的手段】本发明人对具有抗胆碱能M3受体结合作用的化合物进行了研究,发现一种氮杂环桥合环化合物或其盐具有抗胆碱能M3受体结合作用,从而完成了本发明。本发明的氮杂环桥合环化合物具有抗胆碱能M3受体结合作用,并可用作预防和/或治疗慢性阻塞性肺疾病(COPD)、哮喘等炎症性疾病的预防和/或治疗剂。
  • Aza-bridged-ring compound
    申请人:Nagashima Shinya
    公开号:US08367696B2
    公开(公告)日:2013-02-05
    [PROBLEMS] Provided is a compound which has an antagonistic action on a muscarinic M3 receptor and is useful as an active ingredient of a prophylactic and/or therapeutic agent for an inflammatory disease such as a chronic obstructive pulmonary disease (COPD), asthma and the like. [MEANS For SOLVING PROBLEMS] The present inventors have made studies on a compound having an antagonistic action on the binding of a muscarinic M3 receptor, and they have found that an aza-bridged-ring compound or a salt thereof has an antagonistic action on the binding of a muscarinic M3 receptor, thereby completing the present invention. The aza-bridged-ring compound of the present invention has an antagonistic action on the binding of a muscarinic M3 receptor, and can be used as a prophylactic and/or therapeutic agent for an inflammatory disease such as a chronic obstructive pulmonary disease (COPD), asthma and the like.
    【问题】提供了一种化合物,该化合物对于肌肉型M3受体具有拮抗作用,可用作预防性和/或治疗性药物的活性成分,用于治疗炎症性疾病,例如慢性阻塞性肺疾病(COPD),哮喘等。 【解决问题的方法】本发明人对具有对肌肉型M3受体结合具有拮抗作用的化合物进行了研究,并发现一种含氮桥环化合物或其盐对肌肉型M3受体结合具有拮抗作用,从而完成了本发明。本发明的含氮桥环化合物对肌肉型M3受体结合具有拮抗作用,可用作预防性和/或治疗性药物的活性成分,用于治疗炎症性疾病,例如慢性阻塞性肺疾病(COPD),哮喘等。
  • Bridgehead substituted azabicyclic derivatives
    申请人:BEECHAM GROUP PLC
    公开号:EP0287356B1
    公开(公告)日:1996-01-24
  • US4971975A
    申请人:——
    公开号:US4971975A
    公开(公告)日:1990-11-20
查看更多